沃森生物：20价肺炎球菌多糖结合疫苗，目前正在开展Ⅰ期临床研究的准备工作

Group 1 - The company has launched two pneumococcal vaccines: a 13-valent pneumococcal polysaccharide conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine [2] - The company is currently conducting clinical research on a 20-valent pneumococcal polysaccharide conjugate vaccine, which received the Drug Clinical Trial Approval Notification in April 2025 and is preparing for Phase I clinical research [2]